Indefinite Delivery Contract SPE2DR25D9354

The federal contract IDV award SPE2DR25D9354 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

The IDC was awarded under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which aims to establish multiple primary vendor contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, the U.S. Coast Guard, and the U.S. Naval Fleet. The solicitation is expected to be issued in March 2024 and will remain open for 45 days, with awards made on a regional basis to at least three different contractors across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. The acquisition will be conducted as a Lowest Price Technically Acceptable (LPTA) process, with the potential use of a reverse auction to determine the final distribution fees.